Drug Profile
Research programme: anti-flagellin monoclonal antibodies - Rocket Pharmaceuticals
Alternative Names: INO-741; INO-763Latest Information Update: 09 Jan 2018
Price :
$50
*
At a glance
- Originator Inotek Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Bacterial protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Gram-negative infections; Inflammatory bowel diseases
Highest Development Phases
- No development reported Gram-negative infections; Inflammatory bowel diseases
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (Parenteral)